Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Mylan Products Ltd, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom
PARLODEL 5mg Capsules.
| Pharmaceutical Form |
|---|
|
Light blue and white opaque hard gelatine capsules imprinted with ‘5 MG’ on the capsule body. |
Active substance: Ergotaman-3', 6', 18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl-5'-(2-methylpropyl)-, (5’alpha)-mono-methanesulphonate.
Each capsule contains 5.735mg of bromocriptine mesilate (equivalent to 5mg bromocriptine base).
For a full list of excipients see section 6.1
| Active Ingredient | Description | |
|---|---|---|
| Bromocriptine |
Bromocriptine is an inhibitor of prolactin secretion and a stimulator of dopamine receptors. The areas of application of bromocriptine are divided into endocrinological and neurological indications. |
| List of Excipients |
|---|
|
Capsule Content: Silica, colloidal anhydrous Capsule Shell: Indigo carmine (E132) Printing Ink: Shellac (E904) |
Opaque white PV/PVDC blister strip containing 30 PARLODEL 5mg capsules.
Amber glass bottle with a tamper resistant closure containing 100 PARLODEL 5mg capsules.
Not all pack sizes will be marketed.
Mylan Products Ltd, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom
PL 46302/0138
09 October 1981 / 27 October 1997
| Drug | Countries | |
|---|---|---|
| PARLODEL | Australia, Brazil, Germany, Estonia, Spain, France, Hong Kong, Ireland, Italy, Japan, Malta, Netherlands, Poland, Turkey, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
